Gelteq Limited (GELS) vs Johnson & Johnson (JNJ)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GELS | JNJ | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq CM | NYSE |
| Country | Australia | United States |
| Theme | contract-research-cdmo | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $0.45 | $266.30 |
| Return · 1 week | +4.02% | +4.93% |
| Return · 1 month | −18.23% | −2.08% |
| Return · 3 months | −23.80% | −0.16% |
| Return · year to date | −46.62% | +29.86% |
| Return · 1 year | −63.03% | +42.39% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −77.75% | −5.25% |
| 52-week high | $2.01 | $281.07 |
| 52-week low | $0.39 | $184.66 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $4.79M | $641.07B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $23.53K | $1.64B |
| Employees | 7 | 138,200 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 30.29× |
| Price to earnings · forward | — | 21.54× |
| Price to sales | 10.13× | 6.43× |
| Price to book | 0.51× | 7.41× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 18.67× |
| Enterprise value to revenue | 21.39× | 6.65× |
| PEG ratio | — | 2.67 |
| Earnings per share · trailing | -0.44 | 8.63 |
| Profitability | ||
| Gross margin | — | 67.91% |
| Operating margin | −1985.28% | 29.19% |
| Profit margin | −1501.32% | 21.48% |
| Return on equity | −42.93% | 25.74% |
| Return on assets | −17.61% | 8.60% |
| Growth | ||
| Revenue growth | +48.90% | +6.60% |
| Earnings growth | — | −0.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | 36.01 | 57.71 |
| Current ratio | 0.09 | 1.09 |
| Dividend yield | 0.00% | 2.09% |
| Payout ratio | — | 60.72% |
| Trend and volatility | ||
| RSI · 14 | 39.80 | 55.33 |
| ADX · 14 | 28.96 | 15.50 |
| 50-day average | $0.57 | $265.32 |
| 200-day average | $0.67 | $245.78 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 7.28% | 2.75% |
The full GELS analysis
Everything this table leaves out for Gelteq Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GELS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GELS analysisThe full JNJ analysis
Everything this table leaves out for Johnson & Johnson: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the JNJ argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full JNJ analysis